trending Market Intelligence /marketintelligence/en/news-insights/trending/9v80nh9bbu8xlmosjnw-1q2 content esgSubNav
In This List

Former XOMA CEO joins Egalet board

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Former XOMA CEO joins Egalet board

Egalet Corp., a Wayne, Pa.-based maker of pain treatments, appointed John Varian to its board of directors.

Varian was most recently the CEO and director of antibodies developer XOMA Corp., where he led the refocusing and refinancing of the company.

Varian, who also sits on the boards of SELLAS Life Sciences Group Inc. and Versartis Inc., has helped companies establish strategic direction, raise capital and launch pharmaceutical products, the company said in a statement.

"John's successful thirty-five-year career working with biotechnology and specialty pharmaceutical companies will be valuable as we execute on our growth strategy. Specifically, his financial and operational experience will be helpful as we focus on commercial execution and business development," Egalet Chairman Timothy Walbert said in a statement.

Egalet is seeking partners for Egalet-002 — an opioid medication for pain.